OncoMatch/Clinical Trials/NCT06560112
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Is NCT06560112 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including AK104 and AK112 for recurrent ovarian cancer.
Treatment: AK104 · AK112 · Chemotherapy — An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — standard
relapsed after platinum-containing standard chemotherapy
Cannot have received: systemic anti-tumor therapy
Received systemic anti-tumor therapy within 3 weeks prior to randomization
Cannot have received: tumor immunity targeting therapy
Any prior treatments targeting the mechanism of tumor immunity
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify